These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
52 related articles for article (PubMed ID: 2970967)
1. Modification of tumor cells by a low dose of Newcastle disease virus. Augmentation of the tumor-specific T cell response in the absence of an anti-viral response. Von Hoegen P; Weber E; Schirrmacher V Eur J Immunol; 1988 Aug; 18(8):1159-66. PubMed ID: 2970967 [TBL] [Abstract][Full Text] [Related]
2. Modification of tumor cells by a low dose of Newcastle disease virus. II. Augmented tumor-specific T cell response as a result of CD4+ and CD8+ immune T cell cooperation. Schild H; von Hoegen P; Schirrmacher V Cancer Immunol Immunother; 1989; 28(1):22-8. PubMed ID: 2462467 [TBL] [Abstract][Full Text] [Related]
3. Specific eradication of micrometastases by transfer of tumour-immune T cells from major-histocompatibility-complex congenic mice. Schirrmacher V; von Hoegen P; Griesbach A; Schild HJ; Zangemeister-Wittke U Cancer Immunol Immunother; 1991; 32(6):373-81. PubMed ID: 1826094 [TBL] [Abstract][Full Text] [Related]
4. The augmentation of tumor-specific immunity by virus help. III. Enhanced generation of tumor-specific Lyt-1+2- T cells is responsible for augmented tumor immunity in vivo. Yoshioka T; Fukuzawa M; Takai Y; Wakamiya N; Ueda S; Kato S; Fujiwara H; Hamaoka T Cancer Immunol Immunother; 1986; 21(3):193-8. PubMed ID: 2938736 [TBL] [Abstract][Full Text] [Related]
5. Prolongation of survival of mice bearing the Eb and ESb lymphoma by treatment with interferon inducers alone or in combination with Corynebacterium parvum. Storch E; Kirchner H; Schirrmacher V Cancer Immunol Immunother; 1986; 23(3):179-84. PubMed ID: 2431778 [TBL] [Abstract][Full Text] [Related]
6. In situ activation of syngeneic tumour-specific cytotoxic T lymphocytes: intra-pinna immunization followed by restimulation in the peritoneal cavity. Schirrmacher V; Leidig S; Griesbach A Cancer Immunol Immunother; 1991; 33(5):299-306. PubMed ID: 1868488 [TBL] [Abstract][Full Text] [Related]
7. Contribution of the T cell receptor BJ gene to recognition of the P91A tumor antigen in DBA/2 mice. Suzuki S; Masuko-Hongo K; Höger TA; Hong NM; Sasakawa H; Kurokawa M; Miura M; Kurimoto F; Hata K; Mizushima Y; Kobata T; Nishioka K; Yamamoto K; Kato T Cancer Immunol Immunother; 1998 Apr; 46(2):93-103. PubMed ID: 9558005 [TBL] [Abstract][Full Text] [Related]
8. In vitro expansion and analysis of T lymphocyte microcultures obtained from the vaccination sites of cancer patients undergoing active specific immunization with autologous Newcastle-disease-virus-modified tumour cells. Stoeck M; Marland-Noske C; Manasterski M; Zawatzky R; Horn S; Möbus V; Schlag P; Schirrmacher V Cancer Immunol Immunother; 1993 Sep; 37(4):240-4. PubMed ID: 8348563 [TBL] [Abstract][Full Text] [Related]
9. Combinatorial Approaches for Cancer Treatment Using Oncolytic Viruses: Projecting the Perspectives through Clinical Trials Outcomes. Malogolovkin A; Gasanov N; Egorov A; Weener M; Ivanov R; Karabelsky A Viruses; 2021 Jun; 13(7):. PubMed ID: 34209981 [TBL] [Abstract][Full Text] [Related]
10. Less Can Be More: The Hormesis Theory of Stress Adaptation in the Global Biosphere and Its Implications. Schirrmacher V Biomedicines; 2021 Mar; 9(3):. PubMed ID: 33805626 [TBL] [Abstract][Full Text] [Related]
11. Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy. Schirrmacher V; van Gool S; Stuecker W Biomedicines; 2019 Aug; 7(3):. PubMed ID: 31480379 [TBL] [Abstract][Full Text] [Related]
12. Fifty Years of Clinical Application of Newcastle Disease Virus: Time to Celebrate! Schirrmacher V Biomedicines; 2016 Jul; 4(3):. PubMed ID: 28536382 [TBL] [Abstract][Full Text] [Related]
17. New insights into tumor-host interactions in lymphoma metastasis. Umansky V; Schirrmacher V; Rocha M J Mol Med (Berl); 1996 Jul; 74(7):353-63. PubMed ID: 8841948 [TBL] [Abstract][Full Text] [Related]
18. Transloading of tumor cells with foreign major histocompatibility complex class I peptide ligand: a novel general strategy for the generation of potent cancer vaccines. Schmidt W; Steinlein P; Buschle M; Schweighoffer T; Herbst E; Mechtler K; Kirlappos H; Birnstiel ML Proc Natl Acad Sci U S A; 1996 Sep; 93(18):9759-63. PubMed ID: 8790404 [TBL] [Abstract][Full Text] [Related]
19. A role for sialoadhesin-positive tissue macrophages in host resistance to lymphoma metastasis in vivo. Umansky V; Beckhove P; Rocha M; Krüger A; Crocker PR; Schirrmacher V Immunology; 1996 Feb; 87(2):303-9. PubMed ID: 8698395 [TBL] [Abstract][Full Text] [Related]
20. More than one component of the Newcastle disease virus particle is capable of interferon induction. Wertz K; Büttner M; Mayr A; Kaaden OR Vet Microbiol; 1994 Apr; 39(3-4):299-311. PubMed ID: 7518987 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]